Literature DB >> 9833304

Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient. A case report.

K Tanaka1, T Akechi, M Yamazaki, R Hayashi, Y Nishiwaki, Y Uchitomi.   

Abstract

A case of neuroleptic malignant syndrome (NMS) in a 64-year-old man with cancer of the soft palate is reported. During haloperidol treatment for delirium, the patient showed consciousness disturbance with extrapyramidal signs. With discontinuation of haloperidol and replacement by dantrolene and bromocriptine, the patient recovered completely. Although major tranquilizers are widely used in clinical oncology to manage symptoms, NMS has been rarely reported in cancer patients, presumably because of lack of awareness. Early recognition of NMS and prompt treatment may improve the potentially fatal outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833304     DOI: 10.1007/s005200050211

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  2 in total

1.  Methyl p-hydroxybenzoate (E-218) a preservative for drugs and food is an activator of the ryanodine receptor Ca(2+) release channel.

Authors:  D Cavagna; F Zorzato; E Babini; G Prestipino; S Treves
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Neuroleptic malignant syndrome in a patient with tongue cancer: a report of a rare case.

Authors:  Osamu Baba; Kenji Yamagata; Yasushi Tomidokoro; Akira Tamaoka; Hiroyuki Itoh; Toru Yanagawa; Kojiro Onizawa; Hiroki Bukawa
Journal:  Case Rep Dent       Date:  2013-06-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.